Recent Posts
- 3 ESG topics every listed company should consider material right now
- And that’s a wrap 2023! Christmas with IR Department
- This is what the ASX and investors expect for gender diversity on your board
- 5 key lessons any company can take away from our foundational ESG report
- What small caps can take away from Amazon’s move to write emissions data into its supplier standards
Archives
Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene
We speak with Dr Daniel Tillett, Chief Scientific Officer of Race Oncology, about the potential market and efficacy of their drug, Zantrene, which seems likely to change the cancer treatment landscape in the near future.